-
Product Insights
Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Primary immunodeficiency is defined as a weakened immune system that results in repeated infections and other health problems occurring more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea, and diarrhea. The Primary Immune Deficiency drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Immune Deficiency, complete with analysis by stage of development, drug target, mechanism...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...
-
Sector Analysis
Non-Small Cell Lung Cancer – Global Drug Forecast and Market Analysis to 2029
Non-small cell lung cancer (NSCLC) is currently the most common cancer in the world and is the leading cause of cancer mortality in men and women. Of total lung cancer incident cases, approximately 85% are the NSCLC subtype. NSCLC patients are usually diagnosed in the later stages of the disease, resulting in a poor prognosis. Since the last global market forecast (2015–2025), there have been significant changes in the treatment of patients with advanced disease, particularly in the metastatic setting....
-
Sector Analysis
Competitor Landscape: Systemic Sclerosis (Scleroderma)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Systemic Sclerosis (Scleroderma) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Spondyloarthritis
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the spondyloarthritis (SpA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
Competitor Landscape: Lupus
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Lupus market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Sector Analysis
B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2027
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers...
-
Sector Analysis
Digital Landscape: Multiple Sclerosis
The Digital Landscape Multiple Sclerosis report analyzes digital activities undertaken by Pharma in support of disease-modifying therapies for Multiple Sclerosis (MS).
-
Product Insights
Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018" provides an overview of Relapsing Multiple Sclerosis (RMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsing Multiple Sclerosis (RMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...